Incidence of Infections and Predictors of Mortality During Checkpoint Inhibitor Immunotherapy in Patients With Advanced Lung Cancer: A Retrospective Cohort Study.
advanced lung cancer
bacterial infections
immunocompromised hosts
infectious diseases consultation
pneumonia
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
06
02
2021
accepted:
09
04
2021
entrez:
18
6
2021
pubmed:
19
6
2021
medline:
19
6
2021
Statut:
epublish
Résumé
Immune checkpoint inhibitors (ICIs) have revolutionized nonsmall cell lung cancer (NSCLC) treatment and significantly increased overall survival of patients. However, the incidence of concurrent infections and their management is still debated. From August 2015 to October 2019, all consecutive patients with NSCLC who received nivolumab or pembrolizumab as first- or second-line therapy were retrospectively evaluated. At the time of analysis all patients had died. Clinical characteristics of patients, type of infections, and predictors of mortality were analyzed. A total of 118 patients were identified: 74 in the nivolumab group and 44 in the pembrolizumab group. At least 1 infection was recorded in 22% of the nivolumab-group versus 27% of the pembrolizumab-group ( In patients with NSCLC treated with ICIs, multidisciplinary management of concurrent infections may reduce the risk of mortality. Further studies to investigate risk factors for infections, as well as appropriate management strategies and preventive measures in this setting, are warranted.
Sections du résumé
BACKGROUND
BACKGROUND
Immune checkpoint inhibitors (ICIs) have revolutionized nonsmall cell lung cancer (NSCLC) treatment and significantly increased overall survival of patients. However, the incidence of concurrent infections and their management is still debated.
METHODS
METHODS
From August 2015 to October 2019, all consecutive patients with NSCLC who received nivolumab or pembrolizumab as first- or second-line therapy were retrospectively evaluated. At the time of analysis all patients had died. Clinical characteristics of patients, type of infections, and predictors of mortality were analyzed.
RESULTS
RESULTS
A total of 118 patients were identified: 74 in the nivolumab group and 44 in the pembrolizumab group. At least 1 infection was recorded in 22% of the nivolumab-group versus 27% of the pembrolizumab-group (
CONCLUSIONS
CONCLUSIONS
In patients with NSCLC treated with ICIs, multidisciplinary management of concurrent infections may reduce the risk of mortality. Further studies to investigate risk factors for infections, as well as appropriate management strategies and preventive measures in this setting, are warranted.
Identifiants
pubmed: 34141817
doi: 10.1093/ofid/ofab187
pii: ofab187
pmc: PMC8204890
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofab187Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Références
Clin Infect Dis. 2020 Jun 21;:
pubmed: 32564081
Am J Clin Oncol. 1982 Dec;5(6):649-55
pubmed: 7165009
Eur J Cancer. 2016 Feb;54:139-148
pubmed: 26765102
JAMA Oncol. 2016 Dec 1;2(12):1607-1616
pubmed: 27540850
J Oncol Pract. 2014 Sep;10(5):e335-41
pubmed: 25118208
Clin Infect Dis. 2019 Aug 30;69(6):909-920
pubmed: 30520987
Expert Opin Drug Saf. 2020 Jul;19(7):817-842
pubmed: 32394759
J Clin Oncol. 2017 Mar;35(7):709-717
pubmed: 27646942
Lancet Oncol. 2020 Jan;21(1):e55-e65
pubmed: 31908308
Eur Rev Med Pharmacol Sci. 2013 Jan;17(1):8-18
pubmed: 23329518
Clin Infect Dis. 2016 Dec 1;63(11):1490-1493
pubmed: 27501841
Respir Med. 2019 Jan;146:66-70
pubmed: 30665520
Am J Respir Crit Care Med. 2019 Oct 1;200(7):e45-e67
pubmed: 31573350
Cancer Treat Rev. 2017 Jul;58:70-76
pubmed: 28689073
Biomed Pharmacother. 2019 Dec;120:109437
pubmed: 31590992
Clin Lung Cancer. 2019 May;20(3):e247-e250
pubmed: 30635258